`
`ISABELLE L. ORD (Bar No. 198224)
`isabelle.ord@dlapiper.com
`ELIZABETH C. CALLAHAN (Bar No. 323510)
`elizabeth.callahan@dlapiper.com
`DLA PIPER LLP (US)
`555 Mission Street, Suite 2400
`San Francisco, CA 94105-2933
`Tel: 415.836.2500
`Fax: 415.836.2501
`
`ALEXANDER E. WOLF (Bar No. 299775)
`alexander.wolf@dlapiper.com
`DLA PIPER LLP (US)
`2000 Avenue of the Stars, Suite 400 North Tower
`Los Angeles, CA 90067
`Tel: 310.595.3000
`Fax: 310.595.3300
`
`Attorneys for Defendants
`JUST BRANDS USA, INC., JUST BRANDS, INC.,
`and SSGI FINANCIAL SERVICES, INC.
`[Additional Counsel Listed on Signature Page]
`
`UNITED STATES DISTRICT COURT
`CENTRAL DISTRICT OF CALIFORNIA
`MIGUEL RODRIGUEZ, on behalf of
` CASE NO. 2:20-CV-04829-ODW-PLA
`himself and all others similarly situated,
`DEFENDANTS’ NOTICE OF
`Plaintiff,
`MOTION AND MOTION TO STAY
`THE ACTION
`Date:
`January 25, 2021
`Time:
`1:30 p.m.
`Courtroom: 5D
`Judge:
`Hon. Otis D. Wright II
`
`v.
`JUST BRANDS USA, INC., JUST
`BRANDS, INC., and SSGI FINANCIAL
`SERVICES, INC.,
`
`Defendants.
`
`EAST\177576489.1
`
`NOTICE OF MOTION AND MOTION TO STAY ACTION
`CASE NO. 2:20-CV-04829
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`
`
`Case 2:20-cv-04829-ODW-PLA Document 65 Filed 11/23/20 Page 2 of 20 Page ID #:968
`
`NOTICE OF MOTION AND MOTION
`TO PLAINTIFF AND ALL ATTORNEYS OF RECORD:
`PLEASE TAKE NOTICE that on January 25, 2021 at 1:30 p.m., or as soon
`thereafter as this matter may be heard before the Honorable Otis D. Wright, II, in
`Courtroom 5D of this Court, located at 350 West 1st Street, Los Angeles, CA
`90012, defendants Just Brands USA, Inc. (“Just Brands USA”), Just Brands, Inc.
`(“Just Brands”), and SSGI Financial Services, Inc. (“SSGI”) (collectively,
`“Defendants”) will and hereby do move this Court for an order to stay the action.
`First, this action must by stayed under the primary jurisdiction doctrine in
`light of the Food and Drug Administration (“FDA”) issuing draft guidance that will
`likely establish a new regulatory framework for cannabidiol (known as “CBD”),
`an ingredient in products like those at issue here, and also given regulatory
`developments in the States of California and Florida. Second, the Federal Food,
`Drug, and Cosmetic Act (“FDCA”) gives the FDA jurisdiction to subject CBD
`products to a comprehensive regulatory scheme, and Section 297D(c) of the 2018
`Farm Bill expressly reserved the regulatory oversight of hemp consumables under
`the FDCA to the FDA. 7 U.S.C. § 1639r(c); see Snyder v. Green Roads of Fla.
`LLC, 430 F. Supp. 3d 1297, 1308 (S.D. Fla. 2020) (the 2018 Farm Bill “explicitly
`recognized the FDA’s authority to regulate products . . . under the FDCA”) (quoting
`Colette v. CV Scis., Inc., 2020 WL 2739861, at *5 (C.D. Cal. May 22, 2020)).
`Third, the regulation of CBD products requires both the FDA’s expertise and
`uniformity in administration to prevent inconsistent rulings and allow for judicial
`economy and efficiency. Colette, 2020 WL 2739861 at *4 (“[T]he number of CBD
`class actions currently pending in the federal district courts makes clear the danger
`of inconsistent adjudications.”).
`This Motion is based on this Notice of Motion and Motion, the attached
`Memorandum of Points and Authorities, Defendants’ Request for Judicial Notice in
`
`iN
`
`OTICE OF MOTION AND MOTION TO STAY ACTION
`CASE NO. 2:20-CV-04829
`
`EAST\177576489.1
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`26
`27
`28
`
`

